{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:48:52Z","timestamp":1785786532464,"version":"3.56.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,5,15]]},"DOI":"10.1097\/01.tp.0000064083.02120.2c","type":"journal-article","created":{"date-parts":[[2003,12,2]],"date-time":"2003-12-02T06:42:07Z","timestamp":1070347327000},"page":"1437-1443","source":"Crossref","is-referenced-by-count":174,"title":["Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation"],"prefix":"10.1097","volume":"75","author":[{"given":"Melissa B.","family":"King-Biggs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan M.","family":"Dunitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Kay Savik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall I.","family":"Hertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-3-20210129","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S1053-2498(02)00498-9","article-title":"The registry of the international society for heart and lung transplantation: nineteenth official report-2002","volume":"21","author":"Hertz","year":"2002","journal-title":"J Heart Lung Transplant"},{"key":"R3-3-20210129","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0955-470X(10)80014-X","article-title":"Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides","volume":"6","author":"Morris","year":"1992","journal-title":"Transplant Rev"},{"key":"R4-3-20210129","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0009-9120(98)00045-9","article-title":"Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression","volume":"31","author":"Sehgal","year":"1998","journal-title":"Clin Biochem"},{"key":"R5-3-20210129","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1523-1755.2001.00460.x","article-title":"Rapamycin in transplantation: a review of the evidence","volume":"59","author":"Saunders","year":"2000","journal-title":"Kidney Int"},{"key":"R6-3-20210129","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0041-1345(96)00325-9","article-title":"Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo","volume":"29","author":"Nair","year":"1997","journal-title":"Transplant Proc"},{"key":"R7-3-20210129","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1097\/00007890-199810270-00013","article-title":"Immunosuppressive effects and safety of a sirolimus\/cyclosporine combination regimen for renal transplantation","volume":"66","author":"Kahan","year":"1998","journal-title":"Transplantation"},{"key":"R8-3-20210129","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"R9-3-20210129","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/00007890-200101270-00019","article-title":"A worldwide, phase III, randomized, controlled safety and efficacy study of a sirolimus\/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts","volume":"71","author":"MacDonald","year":"2001","journal-title":"Transplantation"},{"key":"R10-3-20210129","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/ki.1996.415","article-title":"Chronic cyclosporin nephropathy: the Achilles\u2019 heel of immunosuppressive therapy","volume":"50","author":"Bennett","year":"1996","journal-title":"Kidney Int"},{"key":"R11-3-20210129","first-page":"1","article-title":"Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: lung rejection study group","volume":"15","author":"Yousem","year":"1996","journal-title":"J Heart Lung Transplant"},{"key":"R12-3-20210129","first-page":"713","article-title":"A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts","volume":"12","author":"Cooper","year":"1993","journal-title":"J Heart Lung Transplant"},{"key":"R13-3-20210129","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/ki.1996.28","article-title":"The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients","volume":"49","author":"Murgia","year":"1996","journal-title":"Kidney Int"},{"key":"R14-3-20210129","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/00007890-200005270-00019","article-title":"Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression and management","volume":"69","author":"Hong","year":"2000","journal-title":"Transplantation"},{"key":"R15-3-20210129","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1097\/00007890-200010270-00021","article-title":"Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience","volume":"70","author":"Dominguez","year":"2000","journal-title":"Transplantation"},{"key":"R16-3-20210129","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0022-5223(19)41485-2","article-title":"Restoration of bronchial arterial circulation after canine lung allotransplantation","volume":"73","author":"Siegelman","year":"1977","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R17-3-20210129","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/S0003-4975(97)83852-0","article-title":"Early and late airway complications after lung transplantation: incidence and management","volume":"63","author":"Kshettry","year":"1997","journal-title":"Ann Thorac Surg"},{"key":"R18-3-20210129","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/0003-4975(94)91038-3","article-title":"Airway complications in lung transplantation","volume":"57","author":"Shennib","year":"1994","journal-title":"Ann Thorac Surg"},{"key":"R19-3-20210129","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0952-7915(96)80090-2","article-title":"Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide","volume":"8","author":"Brazelton","year":"1996","journal-title":"Curr Opin Immunol"},{"key":"R20-3-20210129","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/00007890-200009270-00015","article-title":"Sirolimus (rapamycin) halts and reverses progression of allograft vascular disease in non-human primates","volume":"70","author":"Ikonen","year":"2000","journal-title":"Transplantation"},{"key":"R21-3-20210129","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1097\/00007890-200006150-00007","article-title":"Immunosuppressive therapies for the prevention and treatment of obliterative airway disease in heterotopic rat trachea allografts","volume":"69","author":"Adams","year":"2000","journal-title":"Transplantation"},{"key":"R22-3-20210129","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa012843","article-title":"A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization","volume":"346","author":"Morice","year":"2002","journal-title":"N Engl J Med"},{"key":"R23-3-20210129","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1164\/ajrccm.159.1.9802104","article-title":"Lovastatin induces fibroblast apoptosis in vitro and in vivo. A possible therapy for fibroproliferative disorders","volume":"159","author":"Tan","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"R24-3-20210129","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S1053-2498(00)00232-1","article-title":"RAD in stable lung and heart\/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis","volume":"20","author":"Doyle","year":"2001","journal-title":"J Heart Lung Transplant"},{"key":"R25-3-20210129","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/S1053-2498(01)00421-1","article-title":"Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment","volume":"21","author":"Snell","year":"2002","journal-title":"J Heart Lung Transplant"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/01.TP.0000064083.02120.2C","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:54:35Z","timestamp":1785783275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-200305150-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,15]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003]]}},"URL":"https:\/\/doi.org\/10.1097\/01.tp.0000064083.02120.2c","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5,15]]}}}